Quinidine Gluconate Suppliers & Bulk Manufacturers
Available Forms: Tablet / Oral Solution
Available Strengths: 200 mg, 324 mg, 300 mg/5 mL
Reference Brands: Generic formulations marketed under different names
Category:
Heart Disorder
Quinidine gluconate is available in Tablet / Oral Solution
and strengths such as 200 mg, 324 mg, 300 mg/5 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Quinidine gluconate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Quinidine gluconate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Quinidine is a naturally derived alkaloid and the D-isomer of quinine, originally isolated from the bark of the Cinchona tree and related plant species. First described in 1848, it holds historical significance as the first antiarrhythmic medication, classified as a class Ia agent. Quinidine exerts its therapeutic effects by blocking sodium and potassium currents in cardiac cells, thereby prolonging the action potential and helping to stabilize abnormal heart rhythms. It has been moderately effective in the acute conversion of atrial fibrillation to normal sinus rhythm.
Despite its efficacy, quinidine use declined over the decades due to notable side effects, including a risk of syncope and life-threatening ventricular arrhythmias, a phenomenon historically referred to as “quinidine syncope.” Nevertheless, quinidine retains an important role in the management of specific cardiac conditions where other therapies may be less effective. It is used in the treatment of Brugada syndrome, short QT syndrome, and idiopathic ventricular fibrillation, offering targeted rhythm control for patients with these rare and potentially life-threatening arrhythmias. Quinidine continues to be recognized for its unique mechanism of action and historical significance in the evolution of cardiac arrhythmia management.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing